- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03988556
Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis (SafePBM)
Feasibility and Safety of CareMin650 in Cancer Patients at High Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis Due to the Administration of Radiotherapy: A Prospective Non-comparative Study
Study Overview
Status
Detailed Description
The main objective of the present study is to investigate the feasibility, safety and tolerability of CareMin650 in patients with 1) head & neck cancer at high risk of or suffering from oral mucositis and/or radiation dermatitis due to the administration of radiotherapy with or without chemotherapy with or without targeted therapy, 2) breast cancer at high risk of or suffering from radiation dermatitis due to the administration of radiotherapy.
This is a prospective non-comparative study. Two cohorts of patients will be included, based on the tumour location. Each cohort will be divided into two subgroups according to whether the treatment is for curative or preventive purposes.
- Patients with head & neck cancer (cohort A), either starting radiotherapy with or without chemotherapy with or without targeted therapy (no lesions, prophylactic intent, cohort A1) or having started treatment and presenting with grade 1 to 3 lesions of oral mucositis and/or radiation dermatitis (curative intent, cohort A2).
- Patients with breast cancer requiring radiation therapy (cohort B), either starting radiation therapy (i.e. no lesions, prophylactic intent, cohort B1) or having started treatment and presenting with grade 1 to 3 lesions of radiation dermatitis (curative intent, cohort B2) it is planned to select a maximum number of 72 patients (36 in each cohort)
Consecutive patients will be included in each of the four predefined subgroups, until the target number of patients in each subgroup has been reached.
The photobiomodulation treatment will be initiated at inclusion and will be continued for the duration of radiotherapy (6 to 8 weeks maximum).
The maximum total participation in the study is anticipated to be approximately ten weeks for each patient.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Levallois-Perret, France, 92309
- Institut de radiothérapie et radiochirurgie Hartmann
-
Lille, France, 59000
- Centre Oscar Lambret
-
Nice, France, 06000
- Centre de Haute Energie
-
Paris, France, 75248
- Institut Curie
-
Saint-Priest-en-Jarez, France, 42270
- institut de cancérologie Lucien Neuwirth
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion Criteria common to both cohorts:
- Adult patients (age ≥18 years) accepting to participate in the study and having signed the written informed consent form prior to any protocol-specific procedures.
- Having an ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2.
- Having a life expectancy greater than 3 months according to the investigator medical judgement.
- Having the ability to understand and sign the written informed consent form and willing to comply with protocol requirements.
Specific criteria for inclusion in head and neck cancer cohort (cohort A):
- Patient with histologically proven squamous cell carcinoma of oropharynx, nasopharynx, hypopharynx, larynx or oral cavity with or without prior surgical resection
- Patient with dental examination prior to chemo-radiotherapy and any required dental treatment performed
- In cohort A1 (patient with no oral mucosa or skin lesion, starting radiotherapy), patient scheduled to receive intensity modulated radiation therapy on at least 50% of the oral mucosa at a total dose of at least 40 Gy, alone or associated with chemotherapy or targeted therapies.
- In cohort A2, (on-going radiotherapy), presence of oral mucositis and/or radiation dermatitis grade 1, 2 or 3.
Specific criteria for inclusion in breast cancer cohort (cohort B)
- Patient with histologically proven breast cancer
- After breast-conserving surgery, or total mastectomy if the patient is at high risk of radiodermatitis based on the investigator's judgement.
- In cohort B1, (patient with no skin lesion starting radiotherapy) patient scheduled to receive radiation therapy.
- In cohort B2 (on-going radiotherapy) presence of radiation dermatitis grade 1, 2 or 3.
Exclusion Criteria:
Exclusion Criteria common to both cohorts:
- Any condition that may interfere with adherence to treatment according to the investigator's judgment
- Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.
- Patient with a known polyurethane allergy
- Females patients who are pregnant or breastfeeding
Female patients who do not fall into 1 of the following categories:
- Post-menopausal
- Surgically sterile
Using one of the following birth control methods throughout the duration of the study:
- Intrauterine device (> 14 days)
- Barrier method (condom or diaphragm) with spermicide (> 14 days)
- Hormonal contraception (same dose and same formulation for at least 6 months)
- Patient participating in another clinical trial involving drugs or non-drug therapies aiming to treat or prevent lesions induced by radiotherapy
Specific criteria for non inclusion in head and neck cancer cohort (coh ort A):
- Active bleeding, coagulopathy or pathologic condition that would confer a high risk of bleeding
- Hb < 8g/dL; neutrophils < 1000 mm3; platelets < 50 000/mm3
Specific criteria for non inclusion in breast cancer cohort (cohort B):
- Previous irradiation to the same breast
- Any pre-existing skin disorders located on the chest
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort A1 - Head & neck cancer - Prophylactic intent
Patients with head & neck cancer starting radiotherapy +/- chemotherapy +/- targeted therapy (no lesions, prophylactic intent). Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session. The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing both oral mucositis and radiodermatitis. . |
CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa. For prophylactic treatment, the dose to be delivered has been set at 3J/cm2. If oral mucositis or radiodermatitis occurs in a patient included in a prophylactic cohort, the lesions will be treated with a curative intent and the dose will increase from 3 to 6J/cm2. |
EXPERIMENTAL: Cohort A2 - Head & neck cancer - Curative intent
Patients with head & neck cancer having started radiation therapy and presenting with grade 1 to 3 lesions of oral mucositis and/or radiation dermatitis (curative intent). Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum). The device will be used on each lesion. All existing lesions will be treated whether they are oral mucositis or radiodermatitis lesions. |
CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa. For curative treatment, the dose to be delivered has been set at 6J/cm2. If the lesions of patients included in a curative cohort are resolved before the end of the radiotherapy period, the treatment will be applied with a preventive aim and the dose will decrease from 6 to 3J/cm2. |
EXPERIMENTAL: Cohort B1 - Breast cancer - Prophylactic intent
Patients with breast cancer starting radiation therapy (i.e. no lesions, prophylactic intent). Treatment with CareMin650 will start on the first day of radiotherapy and will be administered during the whole radiotherapy period (6 to 8 weeks maximum), ideally 5 days/week, at least 3 days/week, before or after the radiotherapy session. The device will be used on irradiated areas presenting a risk of radiotherapy-related complications. The prophylactic treatment will aim at preventing radiodermatitis. |
CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa. For prophylactic treatment, the dose to be delivered has been set at 3J/cm2. If oral mucositis or radiodermatitis occurs in a patient included in a prophylactic cohort, the lesions will be treated with a curative intent and the dose will increase from 3 to 6J/cm2. |
EXPERIMENTAL: Cohort B2 - Breast cancer - Curative intent
Patients with breast cancer having started radiation therapy and presenting with grade 1 to 3 lesions of radiation dermatitis (curative intent). Treatment with CareMin650 will start as soon as the lesion is diagnosed and will be administered at each radiotherapy session, during the whole radiotherapy period (6 to 8 weeks maximum). The device will be used on each lesion. All existing lesions will be treated. |
CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa. For curative treatment, the dose to be delivered has been set at 6J/cm2. If the lesions of patients included in a curative cohort are resolved before the end of the radiotherapy period, the treatment will be applied with a preventive aim and the dose will decrease from 6 to 3J/cm2. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurence of adverse events
Time Frame: Continuous (from screening visit to Follow-up visit (10 weeks maximum) + 30 days )
|
This safety outcome combines the measure of the number of subjects experiencing adverse events (AEs), the nature and severity of those AEs and their relationship to the study treatments.
|
Continuous (from screening visit to Follow-up visit (10 weeks maximum) + 30 days )
|
Rate of discontinuation due to AEs
Time Frame: Continuous on 6 to 8 weeks maximum (Inclusion visit to End of radiotherapy visit)
|
Rate of discontinuation due to AEs.
|
Continuous on 6 to 8 weeks maximum (Inclusion visit to End of radiotherapy visit)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin lesions assessment - time of lesion occurrence
Time Frame: Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
time of lesion occurrence
|
Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Skin lesions assessment - size of lesions
Time Frame: Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
size of lesions (centimeters square)
|
Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Skin lesions assessment - location
Time Frame: Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
location
|
Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Skin lesions assessment - Grade
Time Frame: Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Severity grade according to CTCAE V3 (0 (absence) to 5 (death))
|
Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Skin lesions assessment - Time until resolution
Time Frame: Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Time until resolution (defined as lesions that do not require further treatment).
|
Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Oral mucosa lesions assessment - time of lesion occurrence
Time Frame: Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
time of lesion occurrence
|
Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Oral mucosa lesions assessment - size of lesions
Time Frame: Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
size of lesions (centimeters square)
|
Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Oral mucosa lesions assessment - location
Time Frame: Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Location
|
Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Oral mucosa lesions assessment - Grade
Time Frame: Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Severity grade according to CTCAE V3 (0 (absence) to 5 (death))
|
Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Oral mucosa lesions assessment - Time until resolution
Time Frame: Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Time until resolution (defined as lesions that do not require further treatment).
|
Inclusion visit, before each therapeutic session with the device (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Score at visual analogic scale of pain
Time Frame: Inclusion visit, first therapeutic session with the device of each radiotherapy week (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
score at visual analogic scale of pain (continuous values from 0 to 10) completed by patients
|
Inclusion visit, first therapeutic session with the device of each radiotherapy week (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Analgesic consumption
Time Frame: Inclusion visit, first therapeutic session with the device of each radiotherapy week (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Assessment of patients analgesic consumption for the pain induced by the oral mucositis and/or radiation dermatitis lesion(s)
|
Inclusion visit, first therapeutic session with the device of each radiotherapy week (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Xerostomia assessment
Time Frame: First therapeutic session with the device of each radiotherapy week (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Assessment of xerostomia grade (0 to 3)
|
First therapeutic session with the device of each radiotherapy week (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Food intake
Time Frame: Inclusion visit, first therapeutic session with the device of each radiotherapy week (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Assessment of oral lesion(s) consequences on food intake
|
Inclusion visit, first therapeutic session with the device of each radiotherapy week (6 to 8 weeks maximum), end of radiotherapy visit (after 6 to 8 weeks maximum), Follow-up visit (7 to 13 days after last exposition)
|
Patients quality of life
Time Frame: 2 times: Inclusion visit, end of radiotherapy visit (after 6 to 8 weeks maximum)
|
SF-12 questionnaire score (12 questions, 2 subscores: mental quality of life score and physical quality of life score) assessed by patients
|
2 times: Inclusion visit, end of radiotherapy visit (after 6 to 8 weeks maximum)
|
Patients satisfaction
Time Frame: 1 time: end of radiotherapy visit (after 6 to 8 weeks maximum)
|
Questionnaire of satisfaction (developed by the sponsor; 9 questions on pain, comfort, duration of sessions, ability to hold the device alone and global satisfaction) completed by patients
|
1 time: end of radiotherapy visit (after 6 to 8 weeks maximum)
|
Convenience of the device and satisfaction of the operator
Time Frame: 1 time: end of radiotherapy visit (after 6 to 8 weeks maximum)
|
questionnaire of convenience of the device and satisfaction (developed by the sponsor; 12 questions on use, experience with the device, technical settings, duration of sessions and global recommendations) completed by health professionals
|
1 time: end of radiotherapy visit (after 6 to 8 weeks maximum)
|
ECOG Scale of Performance Status
Time Frame: 2 times: Inclusion visit, end of radiotherapy visit (after 6 to 8 weeks maximum)
|
ECOG (Eastern Cooperative Oncology Group) performance status (score from 0 to 5) assessed by the investigator
|
2 times: Inclusion visit, end of radiotherapy visit (after 6 to 8 weeks maximum)
|
Use of the device - Number of sessions
Time Frame: throughout the entire treatment period with the device (Day 1 until 6 to 8 weeks maximum)
|
Number of therapeutic sessions with the device
|
throughout the entire treatment period with the device (Day 1 until 6 to 8 weeks maximum)
|
Use of the device - Frequency of use
Time Frame: throughout the entire treatment period with the device (Day 1 until 6 to 8 weeks maximum)
|
Frequency of therapeutic sessions with the device
|
throughout the entire treatment period with the device (Day 1 until 6 to 8 weeks maximum)
|
Use of the device - Cumulative duration of use
Time Frame: throughout the entire treatment period with the device (Day 1 until 6 to 8 weeks maximum)
|
Cumulative duration of procedures
|
throughout the entire treatment period with the device (Day 1 until 6 to 8 weeks maximum)
|
Use of the device - Cumulative dose
Time Frame: throughout the entire treatment period with the device (Day 1 until 6 to 8 weeks maximum)
|
Cumulative dose delivered
|
throughout the entire treatment period with the device (Day 1 until 6 to 8 weeks maximum)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: René-Jean Bensadoun, MD, Centre de Haute Energie - Nice
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ID-RCB: 2018-A03356-49
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Radiation Dermatitis
-
Chang Gung Memorial HospitalNot yet recruiting
-
German University in CairoAin Shams UniversityCompleted
-
China Medical University HospitalCompletedRadiation DermatitisTaiwan
-
Sheba Medical CenterFerring PharmaceuticalsCompleted
-
Apeiron BiologicsCompleted
-
Lutris Pharma Ltd.CompletedRadiation DermatitisUnited States
-
University of RochesterNational Cancer Institute (NCI)CompletedRadiation-induced Dermatitis
-
University of the PhilippinesRecruitingAcute Radiation DermatitisPhilippines
-
China Medical University HospitalNot yet recruitingBreast Cancer | Radiation Dermatitis
-
Pharm Olam Pharmaceuticals Ltd.UnknownPrevention of Radiation Induced Dermatitis.